Tolerability and pharmacokinetics of intravitreal sirolimus

Mudumba S., Bezwada P., Takanaga H., Hosoi K., Tsuboi T., Ueda K., Kawazu K., Ali Y., Naor J.

2012
Journal of Ocular Pharmacology and Therapeutics

View publication

Therapeutic Area

Back of the eye (BOTE)
Technology

Pharmacology
Categories

Preclinical development

Affiliations

Pharmaceutical and Preclinical Development Department, Santen Incorporated, 2100 Powell Street, Emeryville, CA 94608, United States; Santen Pharmaceutical Co, Ltd., Ikoma-shi, Nara, Japan

Related Publications

Pyridylmethylthio derivatives as VEGF inhibitors. Part 1

Tajima H., Honda T., Kawashima K., Sasabuchi Y., Yamamoto M., Ban M., Okamoto K., Inoue K., Inaba T., Takeno Y., Aono H.

Functional significance of commonly regulated genes in mechanically and chemically induced retinal ganglion cell death in rat eyes

Kageyama M, Ohashi K, Ota T.

Valosin-containing protein modulator KUS121 protects retinal neurons in a rat model of anterior ischemic optic neuropathy

Kikkawa C., Ikeda H.O., Hata M., Iwai S., Tsujikawa A.

View all Back of the eye (BOTE) publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022